



ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006.

Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad.

E-mail : ishitadrugs@gmail.com | info@ishitadrugs.com | URL : www.ishitadrugs.com

Phone : +91 7226995613/14/15 | +91 79 4002 3839

Date: 13.02.2025

To,
The Department of Corporate Services,
BSE Limited.
Floor No. 25, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001.

Scrip Code: 524400

Dear Sir/Madam,

Subject: Integrated Filing (Financials) for the quarter and nine months ended 31st December, 2024

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31st December, 2024, read with BSE Circular No. 20250102-4 dated 02nd January, 2025, we are submitting herewith the Integrated Filing (Financials) for the quarter and nine months ended 31st December, 2024.

Please take the above details on your records.

Thanking You.

For, Ishita Drugs and Industries Limited

Jagdish Agrawal
Managing Director

"Our basic drugs in the service of humanity worldwide"

CIN No. L24231GJ1992PLC017054

D & B D-U-N-S Number - 65-018-0359

Date: 13/02/2025

To,
The Board of Directors,
Ishita Drugs & Industries Limited,
Ahmedabad.

LIMITED REVIEW REPORT

We have reviewed the accompanying of unaudited financial results of **ISHITA DRUGS AND INDUSTRIES LIMITED** for the period **01 Oct 2024 to 31 Dec 2024**. (The Statement) being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing of Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of **Interim financial information performed by the independent auditor of the entity issued by the Institute of Chartered Accountants of India**. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with Indian accounting standards prescribe under section 133 of companies Act, 2013 read with relevant rules issued there under and another recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Of Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of

JAYMIN SHAH & ASSOCIATES

Chartered Accountants AHMEDABAD



CA Mayank Sancheti

M No. :170863

Date: 13/02/2025

Place: Ahmedabad

UDIN: 25170863BMLNFG4417

ISHITA DRUGS AND INDUSTRIES LIMITED

CIN: L24231GJ1992PLC017054

Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand
Ahmedabad – 382170

Website: www.ishitadrugs.com


Contact: +91 7226995613/14/15

Unaudited Financial Results for the Quarter Ended December 31, 2024



Amount in Lacs except Per Share data

Particulars	Quarter Ended			Period Ended		Year Ended
	3 Months Ended	3 Months Ended	3 Months Ended	9 Months Ended	9 Months Ended	12 Months Ended
	Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
	31-Dec-2024	30-Sep-2024	31-Dec-2023	31-Dec-2024	31-Dec-2023	31-Mar-2024
1 INCOME						
Revenue from Operations	413.18	327.42	321.02	1,043.37	1,069.15	1,518.76
Other Income	6.70	5.05	0.63	17.58	17.64	28.02
Total Income	419.89	332.47	321.65	1,060.96	1,086.79	1,546.78
2 EXPENSES						
(a) Cost of Material Consumed	292.28	218.39	236.50	695.88	774.66	1,137.46
(b) Purchase of Stock-In-Trade	5.62	0.00	1.00	9.92	6.40	6.40
(c) Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	(17.51)	5.02	(0.83)	5.57	(3.28)	(14.51)
(d) Employee Benefit Expense	35.73	32.44	34.10	102.57	99.80	133.89
(e) Finance Cost	1.83	0.33	4.11	2.95	7.41	8.98
(f) Depreciation, Depletion and Amortisation Expense	2.79	2.79	3.33	8.38	9.99	11.17
(g) Other Expense	67.35	47.66	27.46	158.42	130.07	164.67
Total Other Expenses	67.35	47.66	27.46	158.42	130.07	164.67
Total Expenses	388.09	306.63	305.66	983.68	1,025.05	1,448.06
3 Total Profit before Exceptional Items and Tax	31.80	25.84	15.99	77.27	61.74	98.73
4 Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
5 Total Profit before Tax	31.80	25.84	15.99	77.27	61.74	98.73
6 Tax Expense						
7 Current Tax	8.00	6.35	4.07	19.25	15.07	24.00
8 Deferred Tax	0.00	0.00	0.00	0.00	0.00	(0.12)
9 Total Tax Expenses	8.00	6.35	4.07	19.25	15.07	23.88
10 Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00	0.00	0.00	0.00	0.00
11 Net Profit Loss for the period from continuing operations	23.80	19.49	11.92	58.02	46.67	74.85
12 Profit / (Loss) from discontinued operations before tax	0.00	0.00	0.00	0.00	0.00	0.00
13 Tax Expenses of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
14 Net Profit / (Loss) from discontinued operations after tax	0.00	0.00	0.00	0.00	0.00	0.00

Jaydevi




15	Share of Profit / (Loss) of associates and joint ventures accounted for using equity method	0.00	0.00	0.00	0.00	0.00	0.00
16	Total Profit / (Loss) for the period	23.80	19.49	11.92	58.02	46.67	74.85
17	Other Comprehensive Income net of Taxes	0.00	0.00	0.00	0.00	0.00	0.00
18	Total Comprehensive Income for the Period	23.80	19.49	11.92	58.02	46.67	74.85
19	Total profit or loss attributable to						
	Profit or loss, attributable to owners of parents	0.00	0.00	0.00	0.00	0.00	0.00
	Total Profit or loss, attributable to non-controlling interests	0.00	0.00	0.00	0.00	0.00	0.00
20	Total comprehensive income for the period attributable to						
	Comprehensive Income for the period attributable to the owners of parents	0.00	0.00	0.00	0.00	0.00	0.00
	Total comprehensive income for the period attributable to the owners of parent non-controlling interests	0.00	0.00	0.00	0.00	0.00	0.00
21	Details of Equity Share Capital						
	Paid-Up Equity Share Capital	299.03	299.03	299.03	299.03	299.03	299.03
	Face Value of Equity Share Capital	10.00	10.00	10.00	10.00	10.00	10.00
22	Details of Debt Securities						
	Paid-Up Debt Capital	0.00	0.00	0.00	0.00	0.00	0.00
	Face Value of Debt Securities	0.00	0.00	0.00	0.00	0.00	0.00
23	Reserves Excluding Revaluation Reserves	0.00	0.00	0.00	0.00	0.00	0.00
24	Debenture Redemption Reserve	0.00	0.00	0.00	0.00	0.00	0.00
25	Earnings Per Share						
(i)	Earnings Per Share for continuing operations						
	Basic Earnings / (Loss) per share from continuing operations	0.80	0.65	0.40	1.94	1.56	2.50
	Diluted Earnings / (Loss) per share from continuing operations	0.80	0.65	0.40	1.94	1.56	2.50
(ii)	Earnings Per Share for discontinued operations						
	Basic Earnings / (Loss) per share from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
	Diluted Earnings / (Loss) per share from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
(iii)	Earnings per Equity Share						
	Basic Earnings / (Loss) per share from continuing and discontinued operations	0.80	0.65	0.40	1.94	1.56	2.50
	Diluted Earnings / (Loss) per share from continuing and discontinued operations	0.80	0.65	0.40	1.94	1.56	2.50

NOTES

1. The above Financial Results were reviewed by the Audit Committee and thereafter were approved and taken on record by the Board of Directors in their meeting held on February 13, 2025.
2. The Limited Review of the results has been completed by the Statutory Auditors of the Company.
3. As per Indian Accounting Standard (IndAS) "Operating Segment", the Company's business falls within a single business segment viz. "Pharmaceutical Business".
4. The financial results for the quarter ended 31st December, 2024 are Ind AS compliant. The management has exercised necessary due diligence to ensure that the financial results give a true and fair view. This information has not been subjected to limited review or audit.
5. Previous quarter's amounts have been re-grouped/re-classified, wherever considered necessary to make them comparable with those of the current quarter.
6. Results are available at Company's website www.ishitadrugs.com and also at www.bseindia.com.

For, **ISHITA DRUGS AND INDUSTRIES LIMITED**

A handwritten signature in blue ink, appearing to read "Jagdish Agrawal".

JAGDISH AGRAWAL**MANAGING DIRECTOR****DIN: 01031687**Place **Ahmedabad**Date **13/Feb/2025**



ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006

Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad

E-mail : ishitadrugs@gmail.com | info@ishitadrugs.com | URL : www.ishitadrugs.com

Phone : +91 7226995613/14/15 | +91 79 4002 3839

QUARTERLY INTEGRATED FILING (FINANCIAL)

- As per circular No SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31st December, 2024, on quarterly integrated filing (Financial):

A. FINANCIAL RESULTS: ANNEXED ABOVE

B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.: **NOT APPLICABLE**

C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES: **NOT APPLICABLE**

D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter): **NOT APPLICABLE FOR THIS QUARTER**

E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONGWITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter): **NOT APPLICABLE FOR THIS QUARTER**

"Our basic drugs in the service of humanity worldwide"

CIN No. L24231GJ1992PLC017054

D & B D-U-N-S Number - 65-018-0359